دورية أكاديمية
Muscle abnormalities worsen after post-exertional malaise in long COVID.
| العنوان: | Muscle abnormalities worsen after post-exertional malaise in long COVID. |
|---|---|
| المؤلفون: | Appelman B; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands.; Amsterdam Institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands., Charlton BT; Department of Human Movement Sciences, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Amsterdam Movement Sciences, Amsterdam, the Netherlands., Goulding RP; Department of Human Movement Sciences, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Amsterdam Movement Sciences, Amsterdam, the Netherlands., Kerkhoff TJ; Department of Human Movement Sciences, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Amsterdam Movement Sciences, Amsterdam, the Netherlands.; Department of Physiology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, the Netherlands.; Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands., Breedveld EA; Department of Human Movement Sciences, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Amsterdam Movement Sciences, Amsterdam, the Netherlands., Noort W; Department of Human Movement Sciences, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Amsterdam Movement Sciences, Amsterdam, the Netherlands., Offringa C; Department of Human Movement Sciences, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Amsterdam Movement Sciences, Amsterdam, the Netherlands., Bloemers FW; Amsterdam Movement Sciences, Amsterdam, the Netherlands.; Department of Trauma Surgery, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands., van Weeghel M; Laboratory Genetic Metabolic Diseases, Core Facility Metabolomics, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands., Schomakers BV; Laboratory Genetic Metabolic Diseases, Core Facility Metabolomics, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands., Coelho P; Serviço de Neurologia, Departamento de Neurociências e Saúde Mental, Hospital de Santa Maria, CHULN, Lisbon, Portugal.; Faculdade de Medicina, Centro de Estudos Egas Moniz, University of Lisbon, Lisbon, Portugal.; Department of (Neuro)pathology, Amsterdam Neuroscience, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands., Posthuma JJ; Department of Trauma Surgery, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.; Flevoziekenhuis, Division of Surgery, Hospitaalweg 1, Almere, the Netherlands., Aronica E; Department of (Neuro)pathology, Amsterdam Neuroscience, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands., Joost Wiersinga W; Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands.; Amsterdam Institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.; Division of Infectious Diseases, Department of Internal Medicine, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands., van Vugt M; Amsterdam Institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands. m.vanvugt@amsterdamumc.nl.; Division of Infectious Diseases, Tropical Medicine, Department of Medicine, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands. m.vanvugt@amsterdamumc.nl., Wüst RCI; Department of Human Movement Sciences, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. r.wust@vu.nl.; Amsterdam Movement Sciences, Amsterdam, the Netherlands. r.wust@vu.nl. |
| المصدر: | Nature communications [Nat Commun] 2024 Jan 04; Vol. 15 (1), pp. 17. Date of Electronic Publication: 2024 Jan 04. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Nature Pub. Group |
| مواضيع طبية MeSH: | COVID-19*/complications , Musculoskeletal Abnormalities*, Humans ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; Case-Control Studies ; Fatigue/etiology ; Muscle, Skeletal ; Pain ; Plaque, Amyloid |
| مستخلص: | A subgroup of patients infected with SARS-CoV-2 remain symptomatic over three months after infection. A distinctive symptom of patients with long COVID is post-exertional malaise, which is associated with a worsening of fatigue- and pain-related symptoms after acute mental or physical exercise, but its underlying pathophysiology is unclear. With this longitudinal case-control study (NCT05225688), we provide new insights into the pathophysiology of post-exertional malaise in patients with long COVID. We show that skeletal muscle structure is associated with a lower exercise capacity in patients, and local and systemic metabolic disturbances, severe exercise-induced myopathy and tissue infiltration of amyloid-containing deposits in skeletal muscles of patients with long COVID worsen after induction of post-exertional malaise. This study highlights novel pathways that help to understand the pathophysiology of post-exertional malaise in patients suffering from long COVID and other post-infectious diseases. (© 2024. The Author(s).) |
| References: | EBioMedicine. 2021 Oct;72:103589. (PMID: 34571363) J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2712-2723. (PMID: 36102002) Lancet Reg Health Eur. 2023 Apr 07;29:100630. (PMID: 37261215) N Engl J Med. 2023 Mar 9;388(10):913-924. (PMID: 36884324) J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2754-2756. (PMID: 36251474) Am J Respir Crit Care Med. 2022 Jan 1;205(1):126-129. (PMID: 34665688) Nat Commun. 2022 Jun 13;13(1):3387. (PMID: 35697699) J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):11-22. (PMID: 34997689) PLoS Pathog. 2022 May 26;18(5):e1010359. (PMID: 35617421) Nature. 2021 Jul;595(7866):283-288. (PMID: 34010947) Scand J Med Sci Sports. 2015 Dec;25 Suppl 4:126-34. (PMID: 26589126) Chest. 2022 Jan;161(1):54-63. (PMID: 34389297) Arch Neurol. 1988 Apr;45(4):435-7. (PMID: 3355400) Cardiovasc Diabetol. 2021 Aug 23;20(1):172. (PMID: 34425843) FASEB J. 2018 Apr;32(4):2110-2123. (PMID: 29217665) Int J Biochem Cell Biol. 2009 Oct;41(10):1837-45. (PMID: 19467914) Eur J Neurol. 2022 Sep;29(9):2832-2841. (PMID: 35661354) Int J Mol Sci. 2020 Feb 06;21(3):. (PMID: 32041178) Sci Transl Med. 2022 Sep 28;14(664):eabq3059. (PMID: 35857629) Int J Mol Sci. 2021 Apr 15;22(8):. (PMID: 33921053) EBioMedicine. 2021 Sep;71:103561. (PMID: 34455390) Front Immunol. 2022 Jan 10;12:746021. (PMID: 35082777) Physiol Meas. 2019 Sep 30;40(9):095008. (PMID: 31518999) Cardiovasc Diabetol. 2022 Sep 21;21(1):190. (PMID: 36131342) J Appl Physiol (1985). 2023 Oct 1;135(4):902-917. (PMID: 37675472) Antioxid Redox Signal. 2015 Dec 10;23(17):1329-50. (PMID: 26067258) JAMA Neurol. 2021 Aug 1;78(8):948-960. (PMID: 34115106) Nat Commun. 2022 Aug 30;13(1):5104. (PMID: 36042189) Eur Respir J. 2021 Aug 26;58(2):. (PMID: 34210791) Clin Neurophysiol. 2023 Apr;148:65-75. (PMID: 36804609) Nat Immunol. 2023 Apr;24(4):604-611. (PMID: 36879067) J Immunoassay Immunochem. 2020 Nov 1;41(6):1000-1009. (PMID: 33353460) Trends Endocrinol Metab. 2023 Jun;34(6):321-344. (PMID: 37080828) Clin Infect Dis. 2023 Feb 8;76(3):e487-e490. (PMID: 36052466) J Appl Physiol (1985). 2021 Jul 1;131(1):158-173. (PMID: 34013752) Nat Med. 2022 Jul;28(7):1461-1467. (PMID: 35614233) Lancet Microbe. 2023 Sep;4(9):e745-e756. (PMID: 37385286) Blood Rev. 2015 May;29(3):171-8. (PMID: 25467962) STAR Protoc. 2022 Apr 16;3(2):101302. (PMID: 35479116) Diagnostics (Basel). 2018 Sep 11;8(3):. (PMID: 30208578) Nature. 2023 Nov;623(7985):139-148. (PMID: 37748514) Lancet Infect Dis. 2023 Apr;23(4):393-395. (PMID: 36967698) J Psychosom Res. 1995 Apr;39(3):315-25. (PMID: 7636775) BMJ Open Respir Res. 2022 Mar;9(1):. (PMID: 35354589) Front Cardiovasc Med. 2021 Nov 30;8:745758. (PMID: 34917659) PLoS One. 2015 Apr 02;10(3):e0121945. (PMID: 25835001) Nat Med. 2022 Aug;28(8):1706-1714. (PMID: 35879616) J Biomed Sci. 2012 Oct 12;19:89. (PMID: 23061754) Lancet Reg Health Eur. 2021 May 27;6:100142. (PMID: 34557833) Microbiol Spectr. 2022 Feb 23;10(1):e0127121. (PMID: 35171025) Annu Rev Biochem. 2022 Jun 21;91:89-106. (PMID: 35320684) Sports Med. 2023 Jan;53(1):51-74. (PMID: 36115933) JCI Insight. 2022 May 9;7(9):. (PMID: 35358096) Front Immunol. 2018 May 04;9:832. (PMID: 29780380) Diagnostics (Basel). 2019 Jul 04;9(3):. (PMID: 31277442) Pediatr Pulmonol. 2023 Jul;58(7):2059-2067. (PMID: 37097045) Nat Rev Microbiol. 2023 Mar;21(3):133-146. (PMID: 36639608) Nature. 2021 Jul;595(7867):426-431. (PMID: 34126625) Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H364-74. (PMID: 19429822) BMJ. 2006 Sep 16;333(7568):575. (PMID: 16950834) Front Immunol. 2021 Nov 15;12:656797. (PMID: 34867935) Biochem J. 2022 Feb 17;479(4):537-559. (PMID: 35195253) EBioMedicine. 2023 Aug;94:104729. (PMID: 37506544) Acta Neuropathol Commun. 2023 Dec 8;11(1):193. (PMID: 38066589) |
| سلسلة جزيئية: | ClinicalTrials.gov NCT05225688 |
| تواريخ الأحداث: | Date Created: 20240104 Date Completed: 20240108 Latest Revision: 20240418 |
| رمز التحديث: | 20240418 |
| مُعرف محوري في PubMed: | PMC10766651 |
| DOI: | 10.1038/s41467-023-44432-3 |
| PMID: | 38177128 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-023-44432-3 |